论文部分内容阅读
目的探讨阿奇霉素与红霉素治疗儿童支原体肺炎的临床疗效及安全性。方法选取2013年6月至2014年12月辽宁北票市中医院收治的78例支原体肺炎患儿作为研究对象,按随机数字表法将其分为对照组和试验组,各39例。对照组患儿静脉滴注红霉素,试验组患儿采用阿奇霉素进行治疗,比较两组患儿退热时间、咳嗽好转时间、肺部啰音消失时间、住院时间、临床疗效及不良反应发生情况。结果试验组患儿的退热时间、咳嗽好转时间、肺部啰音消失时间、住院时间均明显短于对照组,差异均有统计学意义(均P<0.05);试验组患儿治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);试验组患儿胃肠道反应、注射部位疼痛及皮疹发生率均明显低于对照组,差异均有统计学意义(均P<0.05)。结论阿奇霉素治疗支原体肺炎患儿的临床疗效优于红霉素,可以快速有效地改善患儿临床症状,不良反应少,安全可靠。
Objective To investigate the clinical efficacy and safety of azithromycin and erythromycin in children with mycoplasma pneumonia. Methods Seventy eight children with mycoplasmal pneumonia admitted from Beipiao Hospital of Traditional Chinese Medicine from June 2013 to December 2014 in Liaoning Province were selected as study subjects. They were divided into control group and experimental group according to random number table method, with 39 cases in each group. Patients in the control group received intravenous infusion of erythromycin. The patients in the experimental group were treated with azithromycin. The antipyretic time, cough recovery time, pulmonary rales disappearance time, hospital stay, clinical efficacy and adverse reactions were compared between the two groups . Results The children in experimental group had significantly shorter antipyretic time, cough improvement time, pulmonary rales disappearance time and hospitalization time than those in control group (all P <0.05) The effective rate was significantly higher than the control group, the difference was statistically significant (P <0.05); the experimental group of children gastrointestinal reactions, injection site pain and rash incidence were significantly lower than the control group, the difference was statistically significant (both P <0.05). Conclusion Azithromycin in children with mycoplasma pneumonia is superior to erythromycin in clinical efficacy, can quickly and effectively improve the clinical symptoms of children with less adverse reactions, safe and reliable.